Literature DB >> 32409438

Treating acute anxiety in patients with COVID-19.

Elias Khawam1, Hassan Khouli2, Leo Pozuelo1.   

Abstract

At present, there are no firm guidelines for the treatment of COVID-19-related emotional distress. The current approach is based on our knowledge of how to manage anxiety in medically ill patients, taking into consideration all associated medical comorbidities, drug-drug interactions, and the patient's specific needs and preexisting mental illness. Interventions should be implemented at the bedside to augment the patient's own resiliency in coping with these stressful events. A targeted combination of psychopharmacology (targeting acute anxiety and panic symptoms) and psychotherapy (relaxation techniques, breathing exercises, and encouragement) is recommended.
Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.

Entities:  

Year:  2020        PMID: 32409438     DOI: 10.3949/ccjm.87a.ccc016

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  9 in total

Review 1.  COVID-19, Suffering and Palliative Care: A Review.

Authors:  Tan Seng Beng; Carol Lai Cheng Kim; Chai Chee Shee; Diana Ng Leh Ching; Tan Jiunn Liang; Mehul Kumar Narendra Kumar; Ng Chong Guan; Lim Poh Khuen; Lam Chee Loong; Loh Ee Chin; Sheriza Izwa Zainuddin; David Paul Capelle; Ang Chui Munn; Lim Kah Yen; Nik Nathasha Hani Nik Isahak
Journal:  Am J Hosp Palliat Care       Date:  2021-09-16       Impact factor: 2.090

2.  Transcranial direct current stimulation relieves the severe anxiety of a patient with COVID-19.

Authors:  Samuel Katsuyuki Shinjo; Andre Russowsky Brunoni; Alexandre Hideki Okano; Clarice Tanaka; Abrahão Fontes Baptista
Journal:  Brain Stimul       Date:  2020-07-17       Impact factor: 8.955

Review 3.  Beneficial Effects of Exercise on Depression and Anxiety During the Covid-19 Pandemic: A Narrative Review.

Authors:  Shaojuan Hu; Lorelei Tucker; Chongyun Wu; Luodan Yang
Journal:  Front Psychiatry       Date:  2020-11-04       Impact factor: 4.157

4.  The Relationship Between the Implementation of Statutory Preventative Measures, Perceived Susceptibility of COVID-19, and Personality Traits in the Initial Stage of Corona-Related Lockdown: A German and Austrian Population Online Survey.

Authors:  Christiane Eichenberg; Martin Grossfurthner; Jeannine Andrich; Lisa Hübner; Sybille Kietaibl; Stefana Holocher-Benetka
Journal:  Front Psychiatry       Date:  2021-01-27       Impact factor: 4.157

5.  Can Yogic Breathing Techniques Like Simha Kriya and Isha Kriya Regulate COVID-19-Related Stress?

Authors:  Manjari Rain; Balachundhar Subramaniam; Pramod Avti; Pranay Mahajan; Akshay Anand
Journal:  Front Psychol       Date:  2021-04-15

6.  Psychotropics and COVID-19: An analysis of safety and prophylaxis.

Authors:  H Javelot; C Straczek; G Meyer; C Gitahy Falcao Faria; L Weiner; D Drapier; E Fakra; P Fossati; S Weibel; S Dizet; B Langrée; M Masson; R Gaillard; M Leboyer; P M Llorca; C Hingray; E Haffen; A Yrondi
Journal:  Encephale       Date:  2021-09-02       Impact factor: 1.291

7.  New life after near death: Surviving critical COVID-19 infection.

Authors:  B Hodkinson; P Gina; M Schneider
Journal:  Afr J Thorac Crit Care Med       Date:  2021-12-31

8.  Management of psychiatric conditions and delirium during the COVID-19 pandemic across continents: lessons learned and recommendations.

Authors:  Margaret Isioma Ojeahere; Renato de Filippis; Ramdas Ransing; Ruta Karaliuniene; Irfan Ullah; Drita Gashi Bytyçi; Zargham Abbass; Ozge Kilic; Mahsa Nahidi; Nafisatu Hayatudeen; Sachin Nagendrappa; Sheikh Shoib; Chonnakarn Jatchavala; Amine Larnaout; Tanay Maiti; Oluseun Peter Ogunnubi; Samer El Hayek; Maya Bizri; Andre Luiz Schuh Teixeira; Victor Pereira-Sanchez; Mariana Pinto da Costa
Journal:  Brain Behav Immun Health       Date:  2020-09-19

Review 9.  Neuropsychiatric Complications of COVID-19.

Authors:  Zev M Nakamura; Rebekah P Nash; Sarah L Laughon; Donald L Rosenstein
Journal:  Curr Psychiatry Rep       Date:  2021-03-16       Impact factor: 5.285

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.